Synthesis, Characterization, and Application of $ BaTiO_{3} $ Nanoparticles for Anti-Cancer Activity
Abstract Barium titanate ($ BaTiO_{3} $) nanoparticles (BTNPs) have been considered as emerging materials in biomedical sector through last decades due to the excellent physicochemical properties such as dielectric and piezoelectric structures, biocompatibility, and nonlinear optical characteristics. In this study, BTNPs were synthesized via the co-precipitation method using barium carbonate and titanium dioxide by stirring for 5 h. Then, it was annealed at 850 °C for 5 h with five different concentrations: 0.2, 0.4, 0.6, 0.8, and 1 g/mL. The structural, morphological, and optical analyses were demonstrated by different characterization techniques such as X-ray diffraction (XRD), scanning electron microscopy (SEM), energy dispersive X-ray (EDX), thermogravimetric analysis (TGA), Raman, and UV–visible spectroscopy. The perovskite phase of BTNPs, an intense peak at 31.6°, was observed at the lowest concentration (0.2 g/mL), and the average crystalline size was 1.42 nm based on XRD pattern. The results have been justified by SEM and EDX. TGA demonstrated the adequate thermal stability of this material. EDX analysis confirmed the composition of Ti, Ba, and O elements. Raman peaks at 305 $ cm^{−1} $ and 517 $ cm^{−1} $ confirmed the formation of $ BaTiO_{3} $. UV–visible spectra presented that its’ absorbance edge shifted into visible range at 404 nm. Application of BTNPs on breast cancer cell line (MCF-7) presented significant dispersion effect at 0.2, 0.4 and 0.6 g/mL of $ BaTiO_{3} $. A strong toxicity rate of $ BaTiO_{3} $ has been observed against the MCF-7 cell line. Maximum % of cell viability loss, $$\cong$$ 57% was recorded at 200 µg/mL of BTNPs, and minimum % of cell viability loss was observed as 19% at 50 µg/mL of BTNPs. The results presented that a higher concentration of BTPNs dosage was more effective in inhibition of breast cancer cells. Therefore, BTNPs can be recommended as a promising nanomaterial for anti-cancer drug discovery..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Journal of cluster science - 34(2022), 4 vom: 01. Sept., Seite 1745-1755 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fakhar-e-Alam, M. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Anti-cancer properties |
|---|
| Anmerkungen: |
© The Author(s) 2022 |
|---|
| doi: |
10.1007/s10876-022-02346-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2144192030 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2144192030 | ||
| 003 | DE-627 | ||
| 005 | 20240118093720.0 | ||
| 007 | tu | ||
| 008 | 240118s2022 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10876-022-02346-y |2 doi | |
| 035 | |a (DE-627)OLC2144192030 | ||
| 035 | |a (DE-He213)s10876-022-02346-y-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 500 |q VZ |
| 084 | |a 11 |2 ssgn | ||
| 100 | 1 | |a Fakhar-e-Alam, M. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Synthesis, Characterization, and Application of $ BaTiO_{3} $ Nanoparticles for Anti-Cancer Activity |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s) 2022 | ||
| 520 | |a Abstract Barium titanate ($ BaTiO_{3} $) nanoparticles (BTNPs) have been considered as emerging materials in biomedical sector through last decades due to the excellent physicochemical properties such as dielectric and piezoelectric structures, biocompatibility, and nonlinear optical characteristics. In this study, BTNPs were synthesized via the co-precipitation method using barium carbonate and titanium dioxide by stirring for 5 h. Then, it was annealed at 850 °C for 5 h with five different concentrations: 0.2, 0.4, 0.6, 0.8, and 1 g/mL. The structural, morphological, and optical analyses were demonstrated by different characterization techniques such as X-ray diffraction (XRD), scanning electron microscopy (SEM), energy dispersive X-ray (EDX), thermogravimetric analysis (TGA), Raman, and UV–visible spectroscopy. The perovskite phase of BTNPs, an intense peak at 31.6°, was observed at the lowest concentration (0.2 g/mL), and the average crystalline size was 1.42 nm based on XRD pattern. The results have been justified by SEM and EDX. TGA demonstrated the adequate thermal stability of this material. EDX analysis confirmed the composition of Ti, Ba, and O elements. Raman peaks at 305 $ cm^{−1} $ and 517 $ cm^{−1} $ confirmed the formation of $ BaTiO_{3} $. UV–visible spectra presented that its’ absorbance edge shifted into visible range at 404 nm. Application of BTNPs on breast cancer cell line (MCF-7) presented significant dispersion effect at 0.2, 0.4 and 0.6 g/mL of $ BaTiO_{3} $. A strong toxicity rate of $ BaTiO_{3} $ has been observed against the MCF-7 cell line. Maximum % of cell viability loss, $$\cong$$ 57% was recorded at 200 µg/mL of BTNPs, and minimum % of cell viability loss was observed as 19% at 50 µg/mL of BTNPs. The results presented that a higher concentration of BTPNs dosage was more effective in inhibition of breast cancer cells. Therefore, BTNPs can be recommended as a promising nanomaterial for anti-cancer drug discovery. | ||
| 650 | 4 | |a BaTiO | |
| 650 | 4 | |a nanoparticles | |
| 650 | 4 | |a Anti-cancer properties | |
| 650 | 4 | |a Drug discovery | |
| 650 | 4 | |a Inhibition of MCF-7 | |
| 700 | 1 | |a Saddique, Samira |4 aut | |
| 700 | 1 | |a Hossain, Nazia |0 (orcid)0000-0001-7925-0894 |4 aut | |
| 700 | 1 | |a Shahzad, Aamir |4 aut | |
| 700 | 1 | |a Ullah, Inaam |4 aut | |
| 700 | 1 | |a Sohail, Amjad |4 aut | |
| 700 | 1 | |a Khan, Muhammad Junaid Iqbal |4 aut | |
| 700 | 1 | |a Saadullah, Malik |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cluster science |d Springer US, 1990 |g 34(2022), 4 vom: 01. Sept., Seite 1745-1755 |w (DE-627)130895687 |w (DE-600)1042216-X |w (DE-576)023130083 |x 1040-7278 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2022 |g number:4 |g day:01 |g month:09 |g pages:1745-1755 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s10876-022-02346-y |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-CHE | ||
| 912 | |a SSG-OLC-MAT | ||
| 912 | |a SSG-OPC-MAT | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2022 |e 4 |b 01 |c 09 |h 1745-1755 | ||